Furthermore, ERα re-expression by 5-aza-dC, a DNMT inhibitor, was shown to inhibit tumor growth of TNBC cells in vitro and in vivo, indicating that its expression can be modulated by epigenetic mechanisms and restore the sensitivity of TNBC to endocrine therapy9. The gene discussed is ESR1; the disease is neoplasm.